|
|||||
|
|
SGS-742 Novartis |
|
| Authors: | Bullock Roger |
| Affiliation: | The Kingshill Research Centre, Victoria Hospital, Swindon, UK. roger.bullock@kingshill-research.org |
| Abstract: | SGS-742, a GABA(B) antagonist, is being developed by Saegis, under license from Novartis, for the potential treatment of mild cognitive impairment and Alzheimer's disease (AD). In May 2004, Saegis began enrollment in a phase II trial of SGS-742 in mild-to-moderate AD patients. |
| Keywords: | |
| 本文献已被 PubMed 等数据库收录！ | |